Manni Mohyuddin: Carfilzomib is NOT better than bortezomib for newly diagnosed myeloma

Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on X/Twitter:

“In case this needs to be told again. Carfilzomib is NOT better than bortezomib for newly diagnosed myeloma. It has flunked twice in head-to-head randomized attempts. And observational studies cant answer a question better than two large randomized trials.

References:

1. Endurance: KRd versus VRd
2. Clarion: KMP versus VMP

I concede to having seen many examples where switching out V for K has led to deepening of responses. But at a population level, it is not better.”

Source: Manni Mohyuddin/X